Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease

This study has been completed.
Sponsor:
Information provided by:
Kaiser Permanente
ClinicalTrials.gov Identifier:
NCT00371527
First received: August 31, 2006
Last updated: October 16, 2008
Last verified: August 2006
  Purpose

ABSTRACT CONTEXT: Inappropriate antibiotic prescriptions for acute bronchitis is a major public health concern because of antibiotic resistance. Effective therapies for managing the symptoms of acute bronchitis are lacking, however.

OBJECTIVE: Determine if patients with acute bronchitis have better symptom control when treated with inhaled ipratropium.

DESIGN, SETTING, PARTICIPANTS: COUGH STOP was a randomized, double blind, placebo controlled trial comparing ipratropium with placebo in acute bronchitis. Subjects were referred by their primary care provider or from urgent care clinics at a single institution. Subjects had been diagnosed with acute bronchitis and had no significant co-morbidities.

INTERVENTION: Subjects received ipratropium or placebo inhalers, administering 2 puffs four times daily. A structured telephone interview took place 2, 4, and 8 days after enrollment. Medical records were reviewed at 60 days.

OUTCOME: The primary endpoint was improvement in cough symptomology; secondary endpoints included subsequent antibiotic prescriptions and "well being."


Condition Intervention
Bronchitis
Drug: ipratropium

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease

Resource links provided by NLM:


Further study details as provided by Kaiser Permanente:

Primary Outcome Measures:
  • Improvement in cough symptomology

Secondary Outcome Measures:
  • Subsequent antibiotic prescriptions
  • Frequency of follow up visits for similar complaints in the subsequent two months
  • Sense of well being
  • Time away from work or usual activities.

Estimated Enrollment: 200
Study Start Date: October 2002
Estimated Study Completion Date: January 2004
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • cough with or without sputum production for less than 30 days duration; were age 18 through 65; and were willing to follow up by phone for a brief interview at 2, 4, and 8 days after enrollment

Exclusion Criteria:

  • history of COPD; asthma; or other lung disease; had localized lung findings on exam to suggest pneumonia or asthma; chest X-ray (if done) with evidence of pneumonia; purulent nasal discharge or other evidence of bacterial sinus infection; evidence of streptococcal pharyngitis; temperature greater than 101.5 in the preceding 72 hours; treatment of a respiratory tract infection in the last 30 days; pregnancy; breast feeding; actively trying to become pregnant; history of heart failure; history of renal failure or insufficiency with a creatinine greater than 2.0 mg/dl; history of psychiatric illness other than minor depression; currently incarcerated; or were unwilling to sign the consent form.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00371527

Locations
United States, California
South Sacramento Kaiser Permanente
Sacramento, California, United States, 95823
Sponsors and Collaborators
Kaiser Permanente
Investigators
Principal Investigator: Thomas B McIlraith, MD Mercy Medical Group
Principal Investigator: Norman Chow, MD Kaiser Permanente
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00371527     History of Changes
Other Study ID Numbers: CN 01TMcIl 01 B, CN 01TMcIl 01 B
Study First Received: August 31, 2006
Last Updated: October 16, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Kaiser Permanente:
Bronchitis
Acute bronchitis
Ipratropium
Cough
Metered dose inhaler
Antibiotic prescriptions
Sputum production

Additional relevant MeSH terms:
Lung Diseases
Bronchitis
Acute Disease
Respiratory Tract Diseases
Bronchial Diseases
Lung Diseases, Obstructive
Respiratory Tract Infections
Disease Attributes
Pathologic Processes
Ipratropium
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 29, 2014